Transient but not genetic loss of miR-451 is protective in the development of pulmonary arterial hypertension

Pulmonary Circulation

Volumn 3, Issue 4, 2013, Pages 840-850

  Grant, Jennifer S ^a   Morecroft, Ian ^a   Dempsie, Yvonne ^a   van Rooij, Eva ^b   MacLean, Margaret R ^a   Baker, Andrew H ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b MiRagen Therapeutics   (United States)

Author keywords

Hypoxia; microRNA; Migration; Pulmonary vascular disorder; Smooth muscle cell

Indexed keywords

EID: 84992747893     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.1086/674751     Document Type: Article

References (46)

1. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension. I. Clinical and hemodynamic study. Am J Med 1951;11:686–705.
2. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:13S–24S.
3. McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation 2006;114:1417–1431.
4. Caruso P, MacLean MR, Khanin R, et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol 2010;30:716–723.
5. Drake JI, Bogaard HJ, Mizuno S, et al. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol 2011;45: 1239–1247.
6. Flynt AS, Lai EC. Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet 2008;9:831–842.
7. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001;294:862–864.
8. Lagos-Quintana M, Rauhut R, Yalcin A, et al. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12:735–739.
9. Courboulin A, Paulin R, Giguere NJ, et al. Role for miR- 204 in human pulmonary arterial hypertension. J Exp Med 2011;208:535–548.
10. Caruso P, Dempsie Y, Stevens HC, et al. A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ Res 2012;111:290–300.
11. Yang JS, Maurin T, Robine N, et al. Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2- mediated microRNA biogenesis. Proc Natl Acad Sci USA 2010;107:15163–15168.
12. Cifuentes D, Xue H, Taylor DW, et al. A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science 2010;328:1694–1698.
13. Zhan M, Miller CP, Papayannopoulou T, Stamatoyannopoulos G, Song C-Z. MicroRNA expression dynamics during murine and human erythroid differentiation. Exp Hematol 2007;35:1015–1025.
14. Patrick DM, Zhang CC, Tao Y, et al. Defective erythroid differentiation in miR-451 mutant mice mediated by 14–3–3 zeta. Genes Dev 2010;24:1614–1619.
15. Dore LC, Amigo JD, Dos Santos CO, et al. A GATA-1- regulated microRNA locus essential for erythropoiesis. Proc Natl Acad Sci USA 2008;105:3333–3338.
16. Rasmussen KD, Simmini S, Abreu-Goodger C, et al. The miR-144/451 locus is required for erythroid homeostasis. J Exp Med 2010;207:1351–1358.
17. Bergamaschi A, Katzenellenbogen BS. Tamoxifen downregulation of miR-451 increases 14–3–3zeta and promotes breast cancer cell survival and endocrine resistance. Oncogene 2012;31:39–47.
18. Gal H, Pandi G, Kanner AA, et al. MIR-451 and imatinib mesylate inhibit tumor growth of glioblastoma stem cells. Biochem Biophys Res Commun 2008;376:86–90.
19. Wang R, Wang ZX, Yang JS, et al. MicroRNA-451 functions as a tumor suppressor in human non-small cell lung cancer by targeting ras-related protein 14 (RAB14). Oncogene 2011;30:2644–2658.
20. Li X, Sanda T, Look AT, Novina CD, von Boehmer H. Repression of tumor suppressor miR-451 is essential for NOTCH1-induced oncogenesis in T-ALL. J Exp Med 2011; 208:663–675.
21. Bandres E, Bitarte N, Arias F, et al. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res 2009;15:2281–2290.
22. Zhang X, Wang X, Zhu H, et al. Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusion-induced cardiomyocyte death. J Mol Cell Cardiol 2010;49:841–850.
23. Wang X, Zhu H, Zhang X, et al. Loss of the miR-144/451 cluster impairs ischaemic preconditioning-mediated cardioprotection by targeting Rac-1. Cardiovasc Res 2012;94:379–390.
24. White K, Dempsie Y, Nilsen M, et al. The serotonin transporter, gender, and 17 beta oestradiol in the development of pulmonary arterial hypertension. Cardiovasc Res 2011; 90:373–382.
25. White K, Loughlin L, Maqbool Z, et al. Serotonin transporter, sex, and hypoxia: microarray analysis in the pulmonary arteries of mice identifies genes with relevance to human PAH. Physiol Genomics 2011;43:417–437.
26. Dempsie Y, Nilsen M, White K, et al. Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females. Respir Res 2011;12: 159.
27. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation 2010;121:2045–2066.
28. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006;34:D140–D144.
29. Bian HB, Pan X, Yang JS, Wang ZX, De W. Upregulation of microRNA-451 increases cisplatin sensitivity of non-small cell lung cancer cell line (A549). J Exp Clin Cancer Res 2011;30:20.
30. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003; 115:787–798.
31. Patrick DM, Zhang CC, Tao Y, et al. Defective erythroid differentiation in miR-451 mutant mice mediated by 14–3–3zeta. Genes Dev 2010;24:1614–1619.
32. Yu D, dos Santos CO, Zhao G, et al. miR-451 protects against erythroid oxidant stress by repressing 14–3–3zeta. Genes Dev 2010;24:1620–1633.
33. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013–L1032.
34. Morrell NW, Yang X, Upton PD, et al. Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 2001;104:790–795.
35. Jalali S, Ramanathan GK, Parthasarathy PT, et al. Mir-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation. PLoS ONE 2012;7:e46808.
36. Frazziano G, Champion HC, Pagano PJ. NADPH oxidasederived ROS and the regulation of pulmonary vessel tone. Am J Physiol Heart Circ Physiol 2012;302:H2166–H2177.
37. Zhan M, Miller CP, Papayannopoulou T, Stamatoyannopoulos G, Song CZ. MicroRNA expression dynamics during murine and human erythroid differentiation. Exp Hematol 2007;35:1015–1025.
38. Taraseviciene-Stewart L, Kasahara Y, Alger L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001; 15:427–438.
39. Hyvelin JM, Howell K, Nichol A, et al. Inhibition of ρ- kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 2005;97:185–191.
40. Cahill E, Rowan SC, Sands M, et al. The pathophysiological basis of chronic hypoxic pulmonary hypertension in the mouse: vasoconstrictor and structural mechanisms contribute equally. Exp Physiol 2012;97:796–806.
41. Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013–L1032.
42. Brennecke J, Stark A, Russell RB, Cohen SM. Principles of microRNA-target recognition. PLoS Biol 2005;3:e85.
43. Doench JG, Sharp PA. Specificity of microRNA target selection in translational repression. Genes Dev 2004;18:504–511.
44. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform 2011;44:839–847.
45. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 2012;11:860–872.
46. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010;137:376–387.